3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
11
Neoplasms
5
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Head and Neck Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
Docetaxel
8
pembrolizumab
7
Pemetrexed
5
Carboplatin
5
Erlotinib Hydrochloride
4
toripalimab
3
rociletinib
3
fludarabine
3
Radiosurgery
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Gemcitabine
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Bevacizumab
3
lorlatinib
2
atezolizumab
2
Vinorelbine
2
Topotecan
2
Radiotherapy
2
Platinum
2
Itraconazole
2
Irinotecan
2
Interleukin-2
2
Cetuximab
2
Albumin-Bound Paclitaxel
2
vinflunine
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
rovalpituzumab tesirine
×
Thoracic
×
Clear all
NCT02674568
2021-07-30
TRINITY
AbbVie
Phase 2
Completed
342 enrolled
18 charts